BHIC on OTC
BioScience Health Innovations, Inc.
$6.78 down 0.22 (3.14%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Compare with Datacentrex, Inc., SideChannel, Inc. or TechCreate Group Ltd., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
57.0%Gross margin4
12.6%Operating margin4
11.3%Net margin5
208.3%Revenue growth, 20254
43.5%Return on equity4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue43¢$2.4M
- Research and development1¢$37.5K
- Selling, general and admin39¢$2.2M
- Other costs5¢$277.6K
- Income tax1¢$77.0K
- Profit11¢$642.1K
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$172.2K
Out of $172.2K of cash from operations.5
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $5.7M | $1.8M |
| Cost of goods sold | -$2.4M | -$536.1K |
| Gross Profit | $3.2M | $1.3M |
| General and administrative expenses | $2.2M | $1.1M |
| Consulting fees | $315.2K | $75.5K |
| Total Operating Expenses | $2.5M | $1.2M |
| Income (Loss) from Operations | $719.1K | $87.0K |
| Income tax expense | $77.0K | $0 |
| Net Income (Loss) | $642.1K | $87.0K |
| Net income (loss) per common share - basic (in Dollars per share) | $0.06 | $0.01 |
| Net income (loss) per common share - diluted (in Dollars per share) | $0.06 | $0.01 |
| Weighted average common shares outstanding - basic (in Shares) | 11.0M shares | 10.5M shares |
| Weighted average common shares outstanding - diluted (in Shares) | 11.4M shares | 10.9M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $661.9K | $662.5K | |
| Accounts receivable, net | $399.3K | $100.3K | |
| Inventory | $336.3K | $58.3K | |
| Prepaid expense and other current assets | $21.3K | $4.8K | |
| Overpayment to related parties | $137.7K | $21.8K | |
| Deferred tax asset | $2.1K | $0 | |
| Total current assets | $1.6M | $847.8K | |
| Intangible assets | $82.9K | $26.0K | |
| Deposits | $4.4K | $0 | |
| Right-of-use asset | $61.2K | $0 | |
| Total other assets | $148.5K | $26.0K | |
| Total Assets | $1.7M | $873.8K | |
| Accounts payable | $6.3K | $8.2K | |
| Accrued expenses | $8.0K | $6.0K | |
| Income tax payable | $79.0K | $0 | |
| Deferred revenue | $136.6K | $24.3K | |
| Total current liabilities | $229.9K | $38.5K | |
| Series A Convertible Preferred Stock, 1,000,000 designated, 140,000 shares issued and outstanding at December 31, 2025 and 2024 | $14 | $14 | |
| Common stock: $0.0001 par value, 250,000,000 shares authorized; 10,979,058 shares issued and outstanding at December 31, 2025 and 2024 | $1.1K | $4.4K | |
| Additional paid-in capital | $1.2M | $1.2M | |
| Accumulated earnings (deficit) | $301.0K | -$341.1K | |
| Total stockholders equity (deficit) | $1.5M | $835.2K | -$6.8K |
| Total Liabilities and Stockholders Equity (Deficit) | $1.7M | $873.8K | |
| Preferred stock, shares issued (in Shares) | 140.0K shares | 140.0K shares | |
| Preferred stock, shares outstanding (in Shares) | 140.0K shares | 140.0K shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares issued (in Shares) | 11.0M shares | 11.0M shares | |
| Common stock, shares outstanding (in Shares) | 11.0M shares | 11.0M shares | |
| Common stock, shares authorized (in Shares) | 250.0M shares | 250.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | $642.1K | $87.0K |
| Lease cost, net of repayments | -$61.2K | $0 |
| Accounts receivable | -$299.0K | -$63.8K |
| Inventory | -$278.0K | -$20.6K |
| Deferred revenue | $112.3K | $20.4K |
| Deferred tax | -$2.1K | $0 |
| Accrued expenses | $2.0K | $4.5K |
| Accounts payable | -$2.0K | $551 |
| Deposits | -$4.4K | $0 |
| Income tax payable | $79.0K | $0 |
| Prepaid expenses | -$16.5K | -$4.8K |
| Net Cash Provided by Operating Activities | $172.2K | $23.2K |
| Purchase of intangible assets | -$56.9K | -$26.0K |
| Net Cash Used in Investing Activities | -$56.9K | -$26.0K |
| Advances from related parties | $3.0M | $962.8K |
| Repayment to related parties | -$3.2M | -$1.1M |
| Proceeds from the sale of common stock | $0 | $755.0K |
| Net Cash Provided by Financing Activities | -$115.9K | $646.1K |
| Net Increase in Cash | -$592 | $643.3K |
| Cash paid for interest | $0 | $0 |
| Cash paid for income taxes | $0 | $0 |
Compare BioScience Health Innovations, Inc. with another company
Former names
- Nowtransit IncNov 4, 2019 to Mar 13, 20253
Recent filings
- Aug 7, 202610-Q BIOSCIENCE HEALTH INNOVATIONS INC. - FORM 10-Q SEC FILING
- Jul 9, 2026QUALIF
- Jul 6, 20261-A POS
- May 11, 202610-Q
- Apr 2, 20268-K
- Mar 30, 202610-K
- Dec 4, 2025QUALIF
- Dec 2, 2025CORRESP
- Nov 25, 20251-A
- Oct 27, 202510-Q
- Oct 16, 20258-K
- Aug 7, 202510-Q
- May 8, 202510-Q
- Mar 17, 20258-K
- Mar 13, 202510-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceBHIC quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11